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Abstract 25 
In the last decade testosterone replacement therapy (TRT) has been increasingly prescribed to treat 26 
a controversial condition known as ‘late-onset hypogonadism (LOH)’. This syndrome is diagnosed 27 
in men who, for no discernible reason other than older age, obesity or ill health have serum 28 
testosterone concentrations below the normal range for healthy young men and report one or more 29 
of the following symptoms: muscle weakness or wasting, mood, behaviour and cognition related 30 
symptoms and sexual function or libido impairment. However, recent evidence has demonstrated 31 
that testosterone drugs do not substantially ameliorate these symptoms and, more worryingly, that 32 
their long-term use may be associated with severe adverse effects (i.e., increased risk of prostate 33 
cancer, stroke and myocardial infarction, worsening of benign prostatic hyperplasia symptoms, 34 
testicular atrophy). Nonetheless, testosterone drugs have exhibited extraordinary commercial 35 
success and their pharmaceutical sales are steadily rising. Behind this apparently unjustifiable trend 36 
there are deliberate, well designed direct and indirect pharmaceutical marketing initiatives that 37 
exploit the conviction rooted in contemporary society that testosterone can reverse the effects of 38 
ageing and ensure social accomplishment. Commercial mechanisms have laid the foundation for 39 
disease mongering of LOH and also have resulted a considerable expansion of the indications for 40 
treatment. This promotion model deserves particular attention since it is applicable to any drug with 41 
a purportedly favourable risk-benefit ratio not supported by evidence.  42 
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Introduction 48 
The Food and Drug Administration (FDA) approved testosterone as a replacement therapy 49 
only for men who have low testosterone levels attributable to disorders of the testicles, pituitary 50 
gland, or brain that cause hypogonadism (FDA Drug Safety Communication, 2015). However, in 51 
the last decade testosterone products are being increasingly prescribed to treat a controversial 52 
condition known as ‘late-onset hypogonadism (LOH)’. This syndrome, also referred to as ‘age 53 
related hypogonadism’, is associated with advancing age and is characterized by a deficiency in 54 
serum testosterone levels (below the normal range for healthy young men) and by symptoms 55 
reminiscent of hypogonadism in young men, such as sexual dysfunction, muscle weakness, obesity, 56 
osteoporosis, hot flushes, insomnia, fatigue, poor concentration and depression (Wang et al., 2009; 57 
Huhtaniemi and Forti, 2011; Huhtaniemi, 2014). 58 
Late-onset hypogonadism may be caused by age-related primary testicular failure or, more 59 
commonly, by a hypothalamic-pituitary failure. However, the decline of testosterone observed in 60 
the latter scenario is very rarely a direct effect of biological ageing or the consequence of organic 61 
diseases of the hypothalamic-pituitary unit. Most often it is due to the chronic conditions (i.e. 62 
overweight/obesity, diabetes, hypertension, hepatic or renal failure, chronic obstructive lung 63 
disease, and inflammatory arthritis) associated with this form of LOH as well as to the medications 64 
to treat them (Huhtaniemi and Forti, 2011; Huhtaniemi, 2014). 65 
Testosterone products used to treat LOH are commonly known as ‘Low testosterone drugs’ 66 
or, simply, as ‘Low-T drugs’. Furthermore, since age-related testosterone decrease has been 67 
associated with an increase in atherosclerosis and cardiovascular risk, some authors speculated that 68 
replacing testosterone would reduce these risks (Kloner et al., 2016). 69 
Recently, Huo et al. published an interesting systematic review including 156 randomised 70 
controlled trials (RCT) that evaluated the use of testosterone drugs against a placebo or an inactive 71 
comparator in adult men for one or more ‘Low-T’ symptoms and for one or more cardiovascular 72 
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endpoints (i.e. ischemia/angina, congestive heart failure, lipids, inflammatory and coagulation 73 
markers) (Huo et al., 2016). They concluded that the prescription of testosterone supplementation 74 
did not show consistent benefits for cardiovascular risk, sexual function, mood and behaviour, or 75 
cognition and, despite an increase in muscle strength, it did not have beneficial effects on overall 76 
physical function (Huo et al., 2016). Moreover, of particular relevance here, is that the safety of 77 
testosterone consumption is doubtful. In fact it seems to be associated with adverse effects, such as 78 
an increased risk of prostate cancer, strokes and myocardial infarction, worsening symptoms of 79 
benign prostatic hyperplasia and testicular atrophy (FDA Drug Safety Communication, 2015; 80 
McCarthy, 2016). Accordingly, in a recent published safety communication, the FDA required 81 
labelling changes for all testosterone products to reflect the possible increased risks of heart attacks 82 
and strokes associated with testosterone use (FDA Drug Safety Communication, 2015). 83 
Furthermore, testosterone administration has been associated with development of acne, 84 
gynecomastia, peripheral edema, and polycythemia. Injections of testosterone undecanoate rarely 85 
have caused pulmonary oil microembolism  and anaphylactic reactions (Safety of Testosterone 86 
Replacement Therapy, 2016). 87 
 The strength of the evidence in terms of both benefits and risks prompted Huo et al. to 88 
conclude that further trials on this issue are no longer necessary (Huo et al., 2016). Nonetheless, this 89 
conclusion might be premature (Yeap, 2016). In fact, the initial results of the National Institutes of 90 
Health–sponsored Testosterone Trials showed a moderate benefit of testosterone supplementation  91 
with respect to sexual function in older men (Snyder et al., 2016; Orwoll, 2016). Furthermore, 92 
additional evidence has yet to be disclosed: results of four of the Testosterone Trials will soon be 93 
published and an Australian trial (T4DM, ACTRN12612000287831) testing the testosterone 94 
supplementation for the prevention of diabetes mellitus in overweight men with impaired glucose 95 
tolerance is currently ongoing (Snyder et al., 2016; Yeap, 2016). Finally, the supposed beneficial 96 
effect of testosterone supplementation on the risk of stroke and of all-cause mortality is waiting to 97 
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be tested with adequately powered randomised controlled trials (Yeap et al., 2014a; Yeap et al., 98 
2014b; Yeap et al., 2016).  99 
Despite the uncertainties about both the benefits and the safety profile of testosterone 100 
replacement therapy, U.S. pharmaceutical sales of testosterone increased from $324 million in 2002 101 
to $2 billion in 2012 and, surprisingly, are continuing to grow in dozens of countries (Perls and 102 
Handelsman, 2015; Huo et al., 2016).  In fact, according to Global Industry Analysts, Inc. the 103 
global market for Testosterone Replacement Therapy (TRT) is projected to reach US $ 6.5 billion 104 
by 2020 (Global Industry Analysts, Inc., 2015). In this article, we aim to disentangle the possible 105 
reasons for such an apparently unjustifiable commercial success. 106 
The promise of eternal youth and social accomplishment 107 
During the twentieth century, life expectancy rose dramatically amongst the world’s 108 
wealthiest populations. Moreover, continuous progress in the fields of medicine, nutrition, and 109 
public health have also allowed people to live the last part of life in good health. Such a feeling of 110 
well-being is the basis of many people’s desire, despite their advanced age, to have a lifestyle 111 
comparable to that of much younger individuals. In this context, male rejuvenation, defined as a 112 
process in men to both limit the impact of ageing on body image and to experience greater virility, 113 
is growing among middle-aged and older men (Miner and Perelman, 2013). Simple and safe 114 
interventions such as weight reduction, smoking cessation, eating a balanced diet with five fruits 115 
and vegetables a day or a Mediterranean diet, and improving fitness, might help limit the effects of 116 
age (Khaw et al., 2008; Sofi et al., 2010).  117 
 However, clinical data suggest that men prefer the seemingly faster pharmaceutical 118 
approaches to ‘rejuvenation’ (Sigman, 2013). Since the production of many hormones decreases 119 
with age, it has been claimed that hormone replacement therapies might mitigate the effects of time 120 
(Morley, 2013). In this regard testosterone plays a key role. In fact, it is well known that 121 
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testosterone has androgenic effects, contributes to sex drive, and has anabolic effects, including the 122 
promotion of muscle mass, bone density, and maturation (Kloner et al., 2016). Therefore, especially 123 
among western societies, there is a deep-rooted conviction that correcting a testosterone deficiency 124 
can restore all these conditions and reverse the effects of age. Thus, this hormone appears to be the 125 
much sought after hormonal fountain of youth, being evocative of virility, strength, and sexual 126 
vitality (Morley, 2013). Furthermore, thanks to its pivotal function in human interactions, 127 
testosterone is considered to be a ‘social hormone’ (Kirby, 2014). Accordingly, several authors 128 
argue that the role of testosterone might be best conceptualised as a motivator for elevated social 129 
status. Maintaining a high status position requires an increased sensitivity to aversive events and 130 
impending social threats, particularly those that challenge the high social status of an individual 131 
(Eisenegger et al., 2011; Coates et al., 2010; Kirby et al., 2014). Testosterone appears to be able to 132 
influence such processes; in particular, it appears to confer high motivational drive, low fearfulness, 133 
and high stress resilience, either directly or via interactions with other hormones and 134 
neurotransmitter systems (Nyby, 2008; Kirby, 2014).  In other words, testosterone is considered as 135 
responsible for success in contemporary societies that require individuals to be increasingly 136 
competitive in all areas of personal and working life often with their much younger counterparts. Its 137 
promised ability to delay or reverse ageing, and its social relevance, constitute the deepest reasons 138 
for testosterone success and constitute the psychological levers used to design successful marketing 139 
campaigns for ‘Low-T drugs’. 140 
The direct marketing campaign 141 
Direct marketing campaigns play a key role in the success of testosterone products. 142 
Traditional drug promotion strategies are designed to influence physician prescription practices and 143 
include: the activities of pharmaceutical sales representatives, the donation of free drug samples and 144 
various gifts marked with the name of the drug itself, invitations to educational and promotional 145 
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meetings, and the distribution of promotional documents highlighting a drug’s benefits in trials 146 
sponsored by the company (Kessel, 2014). However, the direct marketing strategy that is considered 147 
to be responsible for the success of ‘Low-T drugs’ is the so-called ‘direct-to-consumer 148 
pharmaceutical advertising’ (DTCPA). DTCPA can be defined as an effort by a pharmaceutical 149 
company to promote its prescription products directly to patients, and currently it is allowed only in 150 
the United States, New Zealand and partially in Canada (Abel et al., 2006; Ventola et al., 2011).  151 
 This strategy has grown rapidly over recent decades and it is now the most prominent type 152 
of health communication that the public encounters (Ventola et al., 2011). The advertising of ‘Low-153 
T drugs’ has a very wide target audience that includes men aged between 40 and 80 years who share 154 
one or more frequent symptoms: decrease in libido, lack of energy, sadness, grumpiness, tiredness 155 
after dinner, and the reduced ability to play sport (Singer, 2013). These adverts basically formulate 156 
a diagnosis. Indeed, they induce consumers to believe that they are affected by specific syndromes 157 
defined with catchy medicalised terms such as ‘Low T’ and ‘andropause’. Consumers are persuaded 158 
by these sophisticated marketing techniques that their condition is due to testosterone deficiency, 159 
although it might be really caused by several non-hormonal factors or simply determined by the 160 
normal effects of advancing age (Braun, 2013; Singer, 2013; Perls and Handelsman, 2015). In other 161 
words, the ubiquitous ‘Low-T drugs’ DTCPA not only promote a drug but increasingly reframe and 162 
medicalise human traits to create a need for the drugs (Kessel, 2014).  Proponents argue that 163 
DTCPA educates patients by making them aware of the existence and treatment of a condition and 164 
thus allowing them to take charge of their health (Connors 2009; Ventola 2011). However, the 165 
problem here is that consumers lack the technical expertise to critically evaluate the deceptively 166 
simplified medical science claims (Perls and Handelsman, 2015). As a consequence, ‘Low-T drugs’ 167 
DTCPA may set patients against their doctors, pressuring them for compliant prescribing on 168 
demand and distorting their clinical judgments (Perls and Handelsman, 2015). 169 
The indirect marketing campaign 170 
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In parallel with direct marketing promotions, pharmaceutical companies sponsor their drugs 171 
through indirect marketing campaigns that are at least equally effective (Braun, 2013; Kessel, 172 
2014). These methods of promotion are subtler as they convey messages with a more neutral tone, 173 
avoiding the explicit reference to a brand name (Braun, 2013). Their aim is to influence the opinion 174 
of physicians and of consumers about what conditions can be considered as diseases and when 175 
drugs are needed (Schwartz and Woloshin, 2013). In an interesting perspective on the argument, 176 
Braun, a medical writer, described his own experience of the process of the indirect promotion of 177 
testosterone replacement therapies (TRTs) for ‘Low-T’ (Braun, 2013).  178 
 The success of all indirect marketing campaigns for the promotion of ‘Low-T drugs’ is 179 
based on three strategies: lower the bar for diagnosis (turning ordinary life experiences into 180 
conditions that require medical diagnoses), raise the stakes so that people want to get tested, and 181 
spin the evidence about drug benefits and harms (Schwartz and Woloshin, 2013). Communication 182 
companies funded by pharmaceutical companies often coordinate these commercial initiatives. A 183 
widespread technique in this field is the practice of publishing articles in consumer magazines that 184 
are written by medical writers but signed by academic ‘guest authors’ who are asked to add their 185 
names without fulfilling the authorship criteria. In this case, ‘guest authorship’, is accompanied by 186 
‘ghost-writing’, which occurs when a published article fails to acknowledge the original writer or 187 
the writers’ contribution (Gøtzsche et al., 2009; Sismondo, 2009; Stern and Lemmens, 2011).  188 
 With regard to this practice, Braun reported his involvement in writing articles that adhered 189 
to the paradigm of ‘Low-T’ as a potentially serious condition for which new treatments were 190 
available (Braun, 2013).  In trade magazines, the articles appeared under the by-line of a physician 191 
with no mention of the funder behind the overall marketing effort. This strategy considerably raised 192 
the value of the pieces because the reader perceived the information as objective and free of 193 
industry influence (Braun, 2013).  The practice of ghost-writing within TRT seems to mirror the 194 
approach taken in the field of postmenopausal hormone therapy (HT) and, as a consequence, it is 195 
likely to produce the same results. Marketing messages in credible journals almost certainly 196 
Busnelli et al.,  
9 
 
9 
contributed to the widespread use of HT among millions of women who had no medical indication 197 
for the drug, acting in direct contradiction to the most important ethical rule of all physicians: ‘first, 198 
do no harm’ (Fugh-Berman, 2010). 199 
 Another common strategy of indirect marketing in the field of ‘Low-T’ is the 200 
pharmaceutical companies’ sponsorship of educational materials for patients (Braun, 2013). Again, 201 
the goal here, is to raise awareness of a condition and the availability of a treatment, leaving the 202 
responsibility for the decision to the patient, who should ask his doctor if that specific product is the 203 
right remedy for him (Braun, 2013). Professional medical writers are also often asked to write 204 
consensus statements: conclusions that summarise meetings funded by pharmaceutical companies. 205 
 These recommendations are usually published as a guide to clinical practice. However, in 206 
this case, conflicts of interest can also influence the statement. In fact, the panel may not represent 207 
the true range of opinions that exist on the matter, either because the funders choose the panel 208 
members or because the organisers recruit panel members via the personal recommendations of key 209 
members (Braun, 2013). Accordingly, guidelines about ‘Low-T’ management, some of which are 210 
sponsored by manufacturers of testosterone products, have stretched the definition of hypogonadism 211 
to include functional disorders and unexplained low testosterone levels without any underlying 212 
well-defined pathology (Braun, 2013; Perls and Handelsman, 2015). Physicians also frequently use 213 
the monograph that results from the consensus conference when presenting continuing medical 214 
education lectures funded by pharmaceutical companies, inevitably influencing the audience 215 
prescribing behaviour (Braun, 2013). 216 
Disease mongering  217 
The criteria to diagnose LOH have been the focus of a heated debated for a long time. In fact, 218 
different symptoms appear at different testosterone threshold values. It is therefore very difficult to 219 
define a strict limit between normal and low testosterone (Huhtaniemi, 2014). The panel of experts 220 
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of the International Society for Sexual Medicine (ISSM) and a writing committee formed by the 221 
International Society for the Study of the Aging Male (ISSAM), the International Society of 222 
Andrology (ISA), the European Association of Urology (EAU), the European Academy of 223 
Andrology (EAA) and the American Society of Andrology (ASA)  concluded that men with TT 224 
below 8 nmol/L are likely to have testosterone deficiency and, if their luteinizing hormone (LH) 225 
value resulted high, they recommend to initiate testosterone treatment. Moreover, in men with TT 226 
between 8 and 12 nmol/L and low T symptoms and/or a substantially elevated sex hormone binding 227 
globulin (SHBG) level, they suggest further evaluation and a trial of TRT once other causes of their 228 
symptoms have been excluded (Wang et al., 2008; Dean et al., 2015). 229 
Testosterone cut-off levels suggested by the guidelines are in line with the results of European Male 230 
Ageing Study (EMAS). In this cross sectional study, Wu et al. used a reductive analytic approach to 231 
produce clinical and biochemical criteria for diagnosing LOH in order to prevent the excessive 232 
diagnosis of hypogonadism and the injudicious use of testosterone therapy in older men. They 233 
observed an increased number of sexual symptoms associated with a higher odds ratio for a 234 
decreased threshold value for total testosterone (8.0 to 11.0 nmol per liter). This association was 235 
further strengthened by the addition of free testosterone levels to the analysis. Authors concluded 236 
that LOH can be defined by the presence of three sexual symptoms (i.e. decreased frequency of 237 
morning erection, decreased frequency of sexual thoughts,  erectile dysfunction) associated with a 238 
total testosterone level of less than 11 nmol per liter and a free testosterone level of less than 220 239 
pmol per liter (Wu et al., 2010). By applying these criteria, the overall prevalence of LOH in the 240 
EMAS study population would be 2.1%. The majority of these patients would benefit from weight-241 
loss and lifestyle modification and only a small minority of them from testosterone treatment (Wu 242 
et al., 2010).   243 
Late onset-hypogonadism is thus a well defined condition, which appears to be mostly 244 
irreversible and able to determine a serious deterioration in health. Indeed, in a recent prospective 245 
observational cohort survey, Ahern et al. observed a return to normal testosterone values in only 246 
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4.3% of initially affected subjects per year of follow up.  Moreover they reported a mortality rate in 247 
men with primary hypogonadism 2.5 fold higher than in the whole study population (Ahern et al., 248 
2016). This is compatible with other previous findings which observed a substantially increased 249 
mortality among men affected by LOH (Araujo et al., 2011; Pye et al., 2014).  250 
Despite the efforts to establish strict diagnostic criteria, LOH is constantly at risk of disease 251 
mongering, a phenomenon that widens the boundaries of treatable illness to expand markets for 252 
those who sell and deliver treatments (Moynihan et al., 2002). Both direct and indirect marketing 253 
campaigns fail to emphasize adequately the paramount importance of using the combination of 254 
biochemical measures and stringently defined, symptom-based criteria in order to diagnose LOH 255 
(Wu et al., 2010). Consequently, many patients who start testosterone replacement therapy don’t 256 
really need it. This is not only inappropriate but also dangerous.   In fact, each of the two criteria, 257 
when considered alone, doesn’t have a pathological connotation. Symptoms may be simply the 258 
consequence of ageing and testosterone declines physiologically with increasing age at the rate of 259 
approximately 1% per year from the age of 30 (Wang et al., 2008; Perry et al., 2000; Morley, 260 
2013). Noteworthy, in a study investigating the latter issue, Harman et al. observed that a 261 
substantial proportion of healthy men over 60 years of age have circulating testosterone 262 
concentrations in the range conventionally considered to be hypogonadal (Harman et al., 2001). 263 
Another problem that favours disease mongering is the poor adherence of physicians, especially in 264 
the US, to the clear guidelines of the treatment of male hypogonadism. As proof of this, the FDA 265 
found that testosterone level assessment prior to the initiation of treatment did not occur in 28% of 266 
men who received a new testosterone prescription (Nguyen et al., 2015). These data suggest that 267 
only symptoms were extracted from the definition of LOH and that these symptoms are now used as 268 
unequivocal diagnostic elements in clinical practice. 269 
Finally, the decline of testosterone concentration in the elderly population is often due to 270 
comorbidities such as obesity or chronic diseases. In this regard, the European Male Ageing Study 271 
(EMAS) reported that 75% of men with symptomatic hypogonadism were overweight or obese (Wu 272 
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et al., 2008; Wu et al., 2010; Pfaff and Joels, 2016). These people are often incorrectly considered 273 
as affected by primary LOH and are therefore treated with testosterone. Conversely, proper 274 
management should be aimed at addressing the underlying condition (Perls and Handelsman, 2015). 275 
In support of this, a longitudinal study showed that weight loss may be an effective means to 276 
normalize suppressed testosterone levels (Camacho et al., 2013). 277 
Conclusions 278 
Late onset hypogonadism is a rare but serious condition and affected men might respond 279 
favourably to testosterone treatment. However, the vast majority of men treated with testosterone 280 
replacement therapy don’t need it. Reasons behind this extraordinary widening of indications for 281 
‘Low-T drugs’ prescriptions are the testosterone properties evocative of eternal youth and social 282 
accomplishment, the direct and indirect marketing campaigns and the disease mongering of ‘Low-283 
T’. These mechanisms have managed to bypass the fundamental principles of evidence-based 284 
medicine. In fact, they have brought to success a product with an unknown risk-benefit ratio. The 285 
data on overuse are worrying: almost 95% of testosterone replacement therapy is prescribed in ways 286 
that are inconsistent with guideline recommendations (Jasuja et al., 2015; Morgan et al., 2016). 287 
This scenario inevitably produces a cascade of negative events. On the one hand, a lot of money is 288 
being wasted on unnecessary drugs and, on the other hand, other treatable diseases with similar 289 
symptoms are being ignored in favour of testosterone treatment (Kamerow, 2014). Even more 290 
alarming is that, according to rules currently in force, the ‘Low-T drugs’ campaign constitutes a 291 
successful promotion model that is applicable to any drug.  Dangerously, our society constitutes a 292 
fertile ground for these commercial initiatives. In fact, we live in a sort of 'magic bullet' age, when 293 
people want a very simple solution to complex medical or ageing-related problems that does not 294 
involve them having to do any hard work, like modifying their lifestyle permanently. 295 
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Stricter regulations that control both direct and indirect marketing are probably necessary. 296 
However, more immediately, only the physicians’ intellectual honesty can challenge this drift. In 297 
fact, prescription appropriateness is currently the simplest and most efficacious method to cause this 298 
diseased system to collapse. 299 
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